隶属于 Tourmaline Bio
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006. The company was founded by Sandeep Kulkarni on September 17, 2021 and is headquartered in New York, NY.
相关临床试验
14
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2002
进行中（未招募）
1
7.1%
已完成
2
14.3%
No Longer Available
3
21.4%
招募中
1
7.1%
终止
3
21.4%
撤回
4
28.6%
暂无批准数据
- Novartis has entered a $1.7 billion partnership with Relation Therapeutics to develop treatments for allergic diseases using AI-driven drug discovery platforms that analyze patient datasets and human tissue to identify genetic triggers. - The deal includes $55 million upfront payment with potential milestone payments up to $1.7 billion plus tiered royalties, representing part of Novartis' broader strategy to build a resilient pipeline beyond 2025. - Relation's AI technology aims to nominate genetically validated drug targets faster than traditional discovery methods, potentially improving success rates in a field where roughly 75% of drugs fail in phase 2 trials. - The partnership addresses a significant unmet medical need as atopic diseases affect hundreds of millions of patients worldwide despite heavy R&D investment in the space.
- Novartis raised its compound annual sales growth forecast to 5-6% from 2025 to 2030, driven by eight commercialized assets with multi-billion dollar potential including Kisqali and Scemblix. - The company increased peak sales projections for key drugs, with Kisqali now expected to exceed $10 billion and Scemblix raised to over $4 billion from previous estimates. - Novartis achieved core operating margins of 41.2% in the first nine months of 2025, two years ahead of schedule, with expectations to maintain above 40% margins beginning in 2029. - The pharmaceutical giant completed over $23 billion in strategic acquisitions in 2025, including Avidity Biosciences for $12 billion, while maintaining its dual M&A strategy targeting both early-stage and near-launch assets.
- Tiziana Life Sciences announces advancement of TZLS-501, a fully human anti-IL-6 receptor monoclonal antibody targeting both membrane-bound and soluble forms of IL-6R with dual mechanism of action. - The company's decision follows Novartis' recent $1.4 billion acquisition of Tourmaline Bio, validating increased industry interest in IL-6 pathway therapeutics for inflammatory diseases. - TZLS-501 shows potential for treating multiple conditions including rheumatoid arthritis, acute respiratory distress syndrome, idiopathic pulmonary fibrosis, and various cancers by reducing both receptor signaling and circulating cytokine burden. - Tiziana plans to pursue non-dilutive funding strategies for TZLS-501 development while maintaining focus on its lead program, intranasal foralumab for multiple sclerosis.
- Novartis agreed to acquire New York-based biotech Tourmaline Bio for $1.4 billion, paying $48 per share in cash, representing a 60% premium to the company's Monday closing price. - The acquisition centers on Tourmaline's lead candidate pacibekitug, an anti-IL-6 IgG2 antibody targeting atherosclerotic cardiovascular disease, which could address a significant unmet medical need. - The deal strengthens Novartis's cardiovascular portfolio as the company faces generic competition for key drugs including top-selling heart medicine Entresto later this year. - The transaction has received board approval from both companies and is expected to close in the fourth quarter of 2025.
- Novartis announced the acquisition of Tourmaline Bio for approximately $1.4 billion, offering $48 per share in cash to complement its cardiovascular disease portfolio. - The acquisition centers on pacibekitug, a promising monoclonal antibody targeting systemic inflammation that represents a major risk factor for cardiovascular disease. - Pacibekitug is currently in advanced Phase 2 trials and is considered a Phase 3-capable product that could address high unmet medical needs in cardiovascular care. - The transaction is expected to close in the fourth quarter of 2025, subject to regulatory approvals and the tender of a majority of outstanding Tourmaline shares.
- Tourmaline Bio's antibody drug pacibekitug demonstrated significant reduction in cardiovascular risk biomarkers compared to placebo in Phase 2 trials, but shares fell 18% as investors question its competitive edge against Novo Nordisk's offering. - Schrödinger announced CFO Geoffrey Porges will leave the company amid near-record low share prices, coinciding with plans to lay off 7% of staff as part of cost-cutting measures. - CRISPR Therapeutics is expanding its technological capabilities through a $95 million deal with Sirius Therapeutics to develop SRSD107, a novel siRNA blood thinner designed to minimize bleeding risk.
• TEPEZZA, the first FDA-approved treatment for thyroid eye disease, generated $1.9 billion in sales for 2024, with $460 million in Q4 alone, addressing a critical unmet need for patients with limited treatment alternatives. • The global thyroid eye disease market reached $2.3 billion in 2023 across seven major markets, with continued growth expected through 2034 due to increasing disease awareness and rising prevalence. • Several competitors are developing alternative therapies, including Immunovant's batoclimab and Sling Therapeutics' oral small molecule linsitinib, potentially reshaping the treatment landscape in the coming years.
- Tourmaline Bio's Phase 2 TRANQUILITY trial, assessing pacibekitug in chronic kidney disease patients with elevated C-reactive protein, has exceeded its enrollment target, with topline data expected in Q2 2025. - The company has broadened its Cardiovascular Scientific Advisory Board with the addition of Deepak L. Bhatt and Dipender Gill, enhancing expertise in cardiovascular clinical trials and translational insights. - Abdominal aortic aneurysm has been nominated as a new indication for pacibekitug, expanding its development for inflammation-driven cardiovascular disease, with a Phase 2 trial planned. - Further development in Thyroid Eye Disease is contingent on results from the ongoing Phase 2b spiriTED trial, with updates expected in the second half of 2025.
